$KTTA News

Pasithea Therapeutics Says FDA Grants Orphan Drug Designation To PAS-004 For Treatment Of Amyotrophic Lateral Sclerosis

Pasithea Therapeutics Corp. Receives FDA Orphan Drug Designation For MEK1/2 Inhibitor For Treatment Of Amyotrophic Lateral Sclerosis

Pasithea Therapeutics Q1 EPS $(0.12) Beats $(0.45) Estimate

Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer

Is Pasithea Therapeutics (NASDAQ:KTTA) In A Good Position To Deliver On Growth Plans?

HC Wainwright & Co. Reiterates Buy on Pasithea Therapeutics, Maintains $3 Price Target

Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1)

Pasithea Therapeutics Wins FDA Rare Pediatric Disease Tag For NF1 Drug Affecting ~115,000 Americans

Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity

Pasithea Therapeutics Says FDA Grants Fast Track Designation To PAS-004 For Treatment Of NF1-Associated PN Causing Significant Morbidity

Pasithea Therapeutics Says FDA Grants Fast Track Designation To PAS-004 For Treatment Of NF1-Associated PN Causing Significant Morbidity

Pasithea Therapeutics Corp. (KTTA) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript

Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines

Pasithea Therapeutics Provided Updated Timelines on Its Ongoing Clinical Trials in Advanced Cancer and Adult NF1-PN Patients

HC Wainwright & Co. Initiates Coverage On Pasithea Therapeutics with Buy Rating, Announces Price Target of $3

Insiders Buying Pasithea Therapeutics Might Wish They Invested More, Stock Gains 10%

Lawrence Steinman Bought 201% More Shares In Pasithea Therapeutics

Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock

Pasithea Therapeutics Form4 Filing Shows CEO Tiago Marques Bought 33,333 Shares At An Average Price Of $0.75/Share